Beranda › Kanker Paru › Massachusetts › Boston
Uji klinis Kanker Paru di Boston, MA
62 studi untuk Kanker Paru mencari peserta di lokasi sekitar Boston (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- Boston Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
Menerima peserta
- Dana-Farber Cancer Institute, Boston
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Menerima pesertaFase 3
- Tufts Medical Center, Boston
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Menerima pesertaFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Menerima pesertaFase 3
- Dana-Farber Cancer Institute, Boston
A Study of PHN-012 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1
- PHN-012-001 Site, Boston
A Registry for People With Lung Cancer
Menerima pesertaStudi observasional
- Massachusetts General Hospital Cancer Center (Data Collection Only), Boston
- Brigham and Women's Hospital (Data Collection Only), Boston
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Menerima pesertaFase 2/3
- Dana-Farber Cancer Institute, Boston
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Menerima pesertaFase 2
- Research Site, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Menerima pesertaFase 1/2
- Dana Farber Cancer Institute, Boston
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Menerima pesertaFase 2/3
- Dana-Farber Cancer Institute, Boston
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Menerima pesertaFase 1/2
- Massachusetts General Hospital - Main Campus, Boston
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Menerima pesertaFase 1
- Dana-Farber Cancer Institute, Boston
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Menerima pesertaFase 1/2
- Dana-Farber Cancer Institute, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Menerima pesertaFase 1
- Dana Farber Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Menerima pesertaFase 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Massachusetts General Hospital, Boston
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Menerima pesertaFase 3
- Boston Medical Center, Boston
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Menerima pesertaFase 1/2
- Avenzo Therapeutics Recruiting Site, Boston
Investigating Hereditary Risk In Thoracic Cancers (INHERIT)
Menerima pesertaStudi observasional
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol B
Menerima pesertaStudi observasional
- Massachusetts General Hospital, Boston
Practical Geriatric Assessment in Older Adults With Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiation Therapy
Menerima peserta
- Brigham and Women's Hospital, Boston
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Dana Farber Cancer Institute, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Massachusetts General Hospital Cancer Center, Boston
Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial
Menerima peserta
- Dana-Farber Cancer Institute, Boston
Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study
Menerima peserta
- Dana-Farber Cancer Institute, Boston
EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
Menerima pesertaSukarelawan sehat diterima
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Menerima pesertaFase 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
Menerima pesertaFase 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer
Menerima peserta
- Massachusetts General Hospital, Boston
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Menerima pesertaFase 1
- Massachusetts General Hospital, Boston
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Menerima pesertaFase 1/2
- Dana Farber Cancer Institute, Boston
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
Menerima pesertaStudi observasional
- Dana-Farber Cancer Institute, Boston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Menerima pesertaFase 1
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
Prediction Augmented Screening Initiative
Menerima peserta
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Menerima pesertaFase 1
- Research Site, Boston
- Research Site, Boston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Menerima pesertaFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Menerima pesertaFase 1/2
- Massachusetts General Hospital,, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Menerima pesertaFase 1/2
- Dana Farber Cancer Institute, Boston
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Menerima pesertaFase 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Deep Learning Using Chest X-Rays to Identify High Risk Patients for Lung Cancer Screening CT
Menerima peserta
- Massachusetts General Hospital, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Menerima pesertaFase 1/2
- Massachusetts General Hospital, Boston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Menerima pesertaFase 1/2
- Dana Farber Cancer Institute, Boston
Avecure Flexible Microwave Ablation Probe For Lung Nodules
Menerima peserta
- Beth Israel Deaconess Medical Center, Boston
A Digital Health Intervention to Improve Physical Function and Wellness of Lung Cancer Survivors
Menerima peserta
- Massachusetts General Hospital, Boston
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Menerima pesertaFase 1/2
- Dana-Farber Cancer Institute, Boston
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
Menerima pesertaSukarelawan sehat diterima
- Massachusetts General Hospital (MGH) / Harvard, Boston
Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens
Menerima pesertaSukarelawan sehat diterima
- Brigham and Womens Hospital, Boston
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
Menerima pesertaFase 2
- Massachusetts General Hospital, Boston
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
Menerima pesertaFase 1Sukarelawan sehat diterima
- Massachusetts General Hospital, Boston
Lung Cancer Screening in High-risk Black Individuals
Menerima pesertaSukarelawan sehat diterima
- Massachusetts General Hospital Cancer Center, Boston
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Menerima peserta
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
Stereotactic Magnetic Resonance Guided Radiation Therapy
Menerima peserta
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Image Guided VATS vs. VATS Resection
Menerima peserta
- Brigham and Women's Hospital, Boston
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
Menerima pesertaStudi observasional
- Massachusetts General Hospital, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Menerima pesertaFase 1/2
- Dana Farber Cancer Institute, Boston
Comprehensive Outcomes for After Cancer Health
Menerima pesertaSukarelawan sehat diterima
- Dana Farber Cancer Institute, Boston
DNA Analysis of Blood and Tissue from Patients with Lung Cancer
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Massachusetts General Hospital, Boston
- Harvard School of Public Health, Boston
Molecular and Genetic Analysis of Lung Cancer
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Massachusetts General Hospital, Boston
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
Menerima pesertaStudi observasional
- Boston University Medical Center, Boston
Uji klinis Kanker Paru di kota lain
- Houston, TX78 studi
- New York City, NY60 studi
- Los Angeles, CA45 studi
- Washington, DC41 studi
- Arlington, VA41 studi
- Chicago, IL41 studi
- Nashville, TN40 studi
- Baltimore, MD40 studi
- St. Louis, MO39 studi
- Columbus, OH37 studi
- Philadelphia, PA36 studi
- Seattle, WA33 studi
Studi lain di Boston
- Kanker Payudara111 studi
- Kanker Paru Non-Sel Kecil90 studi
- Kanker (semua jenis)86 studi
- Kanker Kolorektal63 studi
- Kanker Metastatik63 studi
- Kanker Ovarium61 studi
- Kanker Prostat59 studi
- Depresi52 studi
- Kanker Endometrium50 studi
- Gagal Jantung44 studi
- Leukemia Mieloid Akut44 studi
- Kanker Pankreas43 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.